- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 16.05. | ASGCT: Analysts see Rocket gene therapy setting 'a new bar' for efficacy in heart condition | ||
| 16.05. | BioMarin inks $270M Inozyme buyout, bagging phase 3 prospect in first M&A move of the Sabry era | ||
| 16.05. | Eli Lilly strengthens RNA pipeline with $1.3B biobucks hearing loss pact | ||
| 16.05. | HCW Biologics clings on with $5M lifeline to fund phase 1 alopecia trial | ||
| 15.05. | Pathos AI secures $365M series D to fund trial of Novo Nordisk solid tumor drug | ||
| 15.05. | Kinase inhibitor biotech Enliven calls time on phase 1 HER2 solid tumor program | ||
| 15.05. | FDA delays decision on Biohaven's rare disease drug filing, plans adcomm | ||
| 14.05. | RA Capital's biotech incubator lays off staffers: Stat | ||
| 14.05. | ADC Therapeutics drops only clinical-stage drug after reviewing phase 1 leukemia data | ||
| 14.05. | Allogene lays off 28% of staff to extend runway amid delays to CAR-T updates | ||
| 14.05. | Alumis' Acelyrin merger back on track after shareholders unswayed by activist investor | ||
| 14.05. | Novo Nordisk inks $2.2B deal for Septerna's preclinical obesity programs | ||
| 14.05. | Kyverna lays off 16% of staff as autoimmune CAR-T plans pick up pace | ||
| 14.05. | GSK pays $1.2B upfront for Boston Pharmaceuticals' lead liver disease drug | ||
| 13.05. | Arcturus stops work on early-stage vaccine programs in effort to 'streamline resources' | ||
| 13.05. | Erasca enters another era, seeks partner for ph. 3 ex-Novartis asset | ||
| 13.05. | Atara lays off more staff this year despite FDA lifting clinical hold | ||
| 13.05. | GSK axes $625M TIGIT drug as midphase data disappoint, promoting partner iTeos to cut costs | ||
| 13.05. | Leap halves head count, narrows lead cancer drug's focus amid 'difficult market environment' | ||
| 13.05. | Appeals court reignites CRISPR discovery row, raising questions about gene-editing biotech patents | ||
| 13.05. | Dutch biotech Azafaros gains €132M series B to fund phase 3 trials of brain-penetrant drug | ||
| 13.05. | Galapagos gets cold feet over plans to split up company | ||
| 12.05. | Former Inhibikase leader launches new biotech for midstage Parkinson's asset | ||
| 12.05. | Tango dances away from preclinical work to extend cash runway, while Avalo lays out spending options | ||
| 12.05. | Lexeo laid off 15% of staff in April to focus on lead cardiac gene therapies |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .